● Recruiting

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Condition: Hepatocellular Carcinoma · Sponsor: Akeso

PhasePhase 3

Planned participants469

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma

This description comes directly from the study's public registry record.

Talk to the study team

Ting Liu · +86 (0760) 8987 3999 · clinicaltrials@akesobio.com

Always discuss trial participation with your own doctor first.

Locations (4)

Henan Cancer Hospital	Zhengzhou, Henan, China	Recruiting
Hunan Cancer Hospital	Changsha, Hunan, China	Recruiting
Zhongda Hospital Southeast University	Nanjing, Jiangsu, China	Recruiting
Zhejiang Cancer Hospital	Hangzhou, Zhejiang, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06371157